Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-08-06

Clinical Trial Update: Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating MK-6194 for systemic lupus erythematosus in adults has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MK-6194

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: TERMINATED